A stromal-state dichotomy governs recalcitrance or remission in inflammatory bowel disease.

Return to Grants

Publication Year:
2026
Authors:
PubMed ID:
42146514
Public Summary:
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic condition characterized by intestinal inflammation, tissue damage, and periods of relapse. Although treatments targeting the immune system have improved disease management, many patients continue to experience persistent inflammation and inadequate responses to therapy. This study investigated how stromal cells, which provide structural and regulatory support to intestinal tissue, influence disease progression and treatment outcomes. Using human intestinal samples, researchers identified two distinct states of myofibroblasts, specialized stromal cells involved in tissue repair and inflammation. Patients with greater proportions of quiescent myofibroblasts were more likely to experience remission, whereas those with predominantly inflammatory myofibroblasts had approximately 4.6 times higher odds of worsening intestinal disease despite treatment escalation. The inflammatory cells also produced signals associated with cellular aging that disrupted intestinal stem cell function, tissue barrier integrity, and immune defenses. Importantly, the researchers identified endothelin receptor B (EDNRB) inhibition as a potential strategy for reversing harmful stromal cell activity. Experimental findings demonstrated that targeting this pathway could restore healthier cellular functions. These discoveries suggest that treatment resistance in IBD may be influenced by reversible stromal cell states and identify a promising direction for developing more personalized therapies.
Scientific Abstract:
Inflammatory bowel diseases (IBD) remain a relapsing, treatment-refractory disorder marked by progressive tissue injury and inflammation despite expanding immune-targeted therapies. We established a prospective cohort integrating stromal biobanking, functional phenotyping, cross-cohort benchmarking, and outcome modeling to define disease-anchored cellular states. Colonic myofibroblasts from 34 individuals spanning health, ulcerative colitis, and Crohn's disease resolved into two dominant states : inflammatory ( IMFs ) and quiescent ( QMFs ) myofibroblasts. QMF predominance forecasted remission, whereas IMF predominance increased the odds of worsening endoscopic severity despite therapy escalation during follow-up by approximately 4.6-fold, linking early stromal biology to clinical outcomes. Unlike QMFs, IMFs exhibited a senescence-associated secretory phenotype that impaired epithelial stemness, barrier integrity, and innate immune fitness. State-guided prioritization identified EDNRB-antagonism as a high-confidence stromal intervention, reversing pathogenic phenotypes across orthogonal assays and species. Outcome simulation positioned stromal-state reversibility by EDNRB-antagonism as a precision axis, reducing odds of recalcitrance by approximately 96.4% and reframing treatment resistance as a reversible stromal state. GRAPHIC ABSTRACT: In this work, Tindle et al. identify reversible stromal states that govern remission vs. recalcitrant outcomes in IBD and nominate precision reprogramming of pathogenic myofibroblasts as a new therapeutic strategy.